Merck KGaA (XTRA:MRK) is back in focus after Silence Therapeutics agreed to a proposed all-cash acquisition worth about $1.3 billion, a move centered on siRNA rare disease treatments.

Merck KGaA's latest moves around siRNA and oncology arrive after a strong run in the ticker, with a 30-day share price return of 11.17% and a year to date share price gain of 19.00% supporting a 1-year total shareholder return of 30.36%, even though the 5-year total shareholder return has declined 23.28%. This suggests momentum has recently been building as investors reassess both growth prospects and risk around the pipeline.

Spot fresh ideas riding similar biotech and healthcare catalysts by scanning the hand-picked 613 high quality undiscovered gems now moving under most investors' radar.

Bulls see Merck KGaA using Silence Therapeutics and oncology tie ups to reshape its pipeline. Bears point to a 5 year shareholder return decline and rich biotech spend. Which side do the current valuation markers support next?

Most Popular Narrative: 6% Undervalued

Merck KGaA's most followed valuation storyline pegs fair value at about €154 per share, compared with the recent close near €144. This frames today's price against a richer long term cash flow outlook built on AI semiconductors, workflow tools, and rare disease drugs.

The shift in Life Science from individual products toward integrated workflow solutions, supported by recent deals such as JSR chromatography, Unity-SC, HUB Organoids and the pending Bio-Techne transaction, can deepen customer stickiness and sustain double digit growth in Process Solutions revenue and EBITDA pre.

See why 60 investors see Merck KGaA as 6% undervalued .

Result: Fair Value of €154.21 (UNDERVALUED)

Still, the Merck KGaA story can be knocked off course if Healthcare products do not offset Mavenclad expiry or if planned deals integrate more slowly than expected.

Find out about the key risks to this Merck KGaA narrative .

Next Steps

Sentiment around Merck KGaA is mixed, and that is exactly why fresh eyes on the data matter. Act while the story is moving and stress test the bullish angles against the 3 key rewards .

Looking for more Merck KGaA investment ideas?

Do not stop with Merck KGaA. Use the Simply Wall Street Screener to quickly surface fresh, data driven ideas before they move out of reach.

• Target resilient cash generators by reviewing a 200 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet.

• Prioritize durability over drama by scanning a 231 resilient stocks with low risk scores built around stronger balance sheets and steadier risk profiles.

• Hunt for tomorrow's quiet overachievers through a 613 high quality undiscovered gems that remain off most investors' radar today.